Analysis of the molecular landscape that characterises a patient or disease is an evolving area that is increasingly driving discoveries in healthcare.
Onyx is a specialist agency with a laser focus on orphan drugs/rare diseases, regenerative medicine including gene therapy, biosimilars and innovative medical technologies where significant unmet clinical needs exist.
Building on our deep heritage in orphan drugs/rare diseases and regenerative medicines, Onyx delivers engaging made-to-measure programmes which successfully overcome the significant and very specific communications challenges such areas present.
Onyx reflects our ability to navigate complex science and our commitment to developing communications for therapies at the cutting edge of medicine using a mix of traditional channels, exciting new innovations in the digital space and avant-garde creativity.
Mantra.
Cutting-edge healthcare. Cutting-edge communications.
Recent Highlights.
Cell Therapy Manufacturing & Gene Therapy Congress in Brussels 2016
Howard Sinclair presenting at the Cell Therapy Manufacturing & Gene Therapy Congress in Brussels earlier this year, a particular honour for the Onyx team.
Vacancies.
We’re always looking for brilliant people to join our teams! Click the link to find out more about becoming part of Prime Global, view available roles, and apply.
Interesting Challenges.
Random Fact.
An estimated 350 million people worldwide have a rare disease and 30% of children with rare diseases die before their 5th birthday.* Thirty-five percent of deaths in the first year of life are caused by rare diseases.*
*Source: www.globalgenes.org
News.
-
Evolving applications of omics in healthcare
Prime Global 25 May, 2022Evolving applications of omics in healthcareread more >> -
Haemophilia awareness: building trusted relationships between patients and industry
Prime Global 19 April, 2022Haemophilia awareness: building trusted relationships between patients and industryread more >>Haemophilia is a lifelong genetic disorder characterised by excessive bleeding.(1) Despite the existence of treatments for haemophilia, the condition continues to have major impacts on quality of life, for example in the areas of pain (acute and chronic), joint mobility, and physical function.(1) To mark World Haemophilia Day on 17 April, Prime Patient partnered with sister agency HCD Economics, a consultancy specialising in haemophilia patient research, and haemophilia advocate Laurence Woollard to better understand the existing relationship between patients and industry and how meaningful improvements can be made to the lives of people living with haemophilia (PwH).
-
What do developmental disability advocates want Pharma to know?read more >>Prime Patient team up with Jess Duggan from the SynGAP Research Fund to better understand what this advocacy group wants Pharma to know this Developmental Disabilities Awareness Month.
Get in touch.
We’re always happy to hear from you
Use the contact form or get full details for each of our offices around the world.
Contact us